A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 751 participants.
Also called NCT01682759
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 751 participants
- Sponsor
- Registry
-
NCT01682759
-
- Other papers using this trial's data
- A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01682759. Randomized; double masking; primary purpose treatment. Start 2012-09-10 (actual); primary completion 2015-01-26 (actual). Results posted on 2016-02-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Omarigliptin
- Intervention (Drug)
- Placebo to Omarigliptin
- Intervention (Drug)
- Glimepiride
- Intervention (Drug)
- Glimepiride Placebo
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Insulin Glargine
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01682759- Content hash
a1de1806e66b45beae91f69319da95dcb95220a2852b1eb28fb30076f228ba39